[Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
In patients with differentiated thyroid carcinoma, long-term inhibition of thyrotropin (TSH) secretion through levothyroxine administration is required when there is evidence of persistent or recurrent disease. In these cases, levothyroxine doses should be monitored to achieve the objectives of inhibiting TSH and avoiding clinical hyperthyroidism. The possibility that suppressive therapy may produce deleterious effects is still controversial, mainly in elderly patients. There are many studies on the potential harmful effects of suppressive therapy on various organs and systems with discrepant results. However, there is no scientific evidence that the clinical impact of these effects is significant.
Departament de Medicina, Universitat Autònoma de Barcelona, Badalona, Barcelona, España. reverter.germanstrias@gencat.cat
Jordi L
JL
Reverter
Eulàlia
E
Colomé
D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000188:drug therapy*; D000368:Aged; D016723:Bone Remodeling / Q000187:drug effects; D002291:Carcinoma, Papillary / Q000097:blood / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003072:Cognition Disorders / Q000139:chemically induced; D005598:Fractures, Spontaneous / Q000139:chemically induced; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D012306:Risk; D019851:Thrombophilia / Q000139:chemically induced; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy*; D013972:Thyrotropin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D013972:Thyrotropin; D013974:Thyroxine